Navigation Links
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Date:11/30/2007

f the world's leading pharmaceutical companies with health care sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion health care business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over three billion in savings to more than one million patients throughout the U.S. and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com

ZACTIMA is a registered trademark of the AstraZeneca group of companies.

(1) Natale RB et al. ZD6474 versus gefitinib in patients with advanced

NSCLC: Final results from two-part, double-blind randomized phase II

trial. Journal of Clinical Oncology, Vol 24, No 18S, 2006: 7000.

(2) Heymach JV et al. Randomized, Placebo-Controlled Phase II Study of

Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung

Cancer Journal of Clinical Oncology, Vol 25, No 27, 2007: 4270-4277.


'/>"/>
SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
(Date:7/31/2014)... 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... second quarter 2014, on Thursday, August 7, 2014 before ... live webcast and conference call at 8:00 a.m. Eastern ... will host the call and webcast to discuss financial ... be accessed by calling (800) 708-4540 (domestic) or (847) ...
(Date:7/31/2014)... N.J. , July 31, 2014  Celsion Corporation ... Company will host a conference call to discuss its ... on Thursday, August 7, 2014. To participate in the ... America ) or 1-785-830-1924 (International/Toll) and ask for ... Code: 8283269) to register ten minutes before the call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... Clinic,s Top 10 Medical Innovations for 2010 list features a ... developed to treat everything from deafness and Parkinson,s disease to ... devices and therapies was selected by a panel of Cleveland ... Cleveland Clinic,s 2009 Medical Innovation Summit , which ...
... Medco Health Solutions, Inc. (NYSE: MHS ) is ... getting the most value out of their Medicare prescription drug ... different plan options - Choice , Access , ... access to a vast array of medications, pharmacy locations, and ...
Cached Medicine Technology:Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 2Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 3Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 4Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 2Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 3Medco's 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs 4
(Date:7/31/2014)... of adults with ADHD improve when their ADHD ... College of Medicine researchers., At least 25 percent ... a parent with ADHD. , "Parents with ADHD ... parenting techniques, including inconsistent disciplinary practices, making ineffectual ... Waxmonsky, associate professor of psychiatry. "Having a parent ...
(Date:7/31/2014)... 2014 Jacuzzi Luxury Bath, ... has launched a new and improved website to meet ... The Jacuzzi Luxury Bath website has been redesigned to ... and quality represented by the company’s products. The design ... and inspirational bathroom applications. “The site reflects our Jacuzzi® ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
(Date:7/31/2014)... According to a new market report ... Market - Global Forecast, Market Share, Size, Growth and ... fixation devices market is estimated at USD 6.1 billion ... CAGR of 7.2% from 2014 to 2019, to reach ... Globally, the orthopedic trauma fixation devices market is witnessing ...
Breaking Medicine News(10 mins):Health News:Parenting skills improve in ADHD parents with medication 2Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 2Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 3
... Allows Pharmaceutical Brand Managers to Build Patient-Flow Models ... Decision Resources, one of the world,s leading ... healthcare issues, finds that use of Novartis, Diovan ... Cozaar is influenced by physician perception that the ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and ... a new healthcare reform coalition:"PhRMA echoes the sentiment shared ... is critical for all Americans to have access to ... central goal in mind, we are working with a ...
... stroke specialists, especially in rural or other underserved areas; ... a "mini" or "warning" stroke, should be treated with ... two separate scientific statements and a policy statement published ... Association . , Telemedicine Statement Highlights: , ...
... May 11 David Cornfield, MD, the chief ... Lucile Packard Children,s Hospital at Stanford, has been ... (SPR).(Photo: http://www.newscom.com/cgi-bin/prnh/20090511/SF14213 )Beginning this month, Cornfield ... pediatricians for a one-year term. "It,s a great ...
... WASHINGTON, May 11 President Obama and U.S. Senate ... protection laws as suggested by health insurers last week, ... said Consumer Watchdog in a letter to the president ... every state over the last 10 years were made ...
... run on behalf of 1.275 million Americans living with spinal ... Dana Reeve Foundation today announced Matthew Reeve, son of Christopher ... Reeve Foundation, will run the 2009 ING New York City ... inspired to compete on behalf of the 1.275 million Americans ...
Cached Medicine News:Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 2Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 3Health News:PhRMA Statement on Healthcare Reform Coalition 2Health News:PhRMA Statement on Healthcare Reform Coalition 3Health News:PhRMA Statement on Healthcare Reform Coalition 4Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Packard/Stanford Physician to Lead Society for Pediatric Research 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 3Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 3
... Package is a solid solution ... The package includes the Vibratome ... mounting blocks, v-block adapter, specimen ... rotating stage assembly for ease ...
... Professional Package is the best ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a sapphire blade for the ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... System provides a versatile means of sectioning ... The 1500 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effect inherent in ...
Medicine Products: